Education and Training
Bariatric Atrial Restoration of Sinus Rhythm
The objective of this study is to determine whether bariatric surgery followed by Atrial Fibrillation (AF) catheter ablation is superior to AF catheter ablation alone in the management of atrial fibrillation in patients with morbid obesity.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Bariatric surgery
- procedure: Atrial Fibrillation (AF) Catheter Ablation
Eligibility
Inclusion Criteria:
- Symptomatic persistent or paroxysmal AF refractory to at least one antiarrhythmic
agent
- EF > 40%
- BMI > 40 or BMI > 35 and at least one of the following co-morbidities:
- Type 2 Diabetes Mellitus (by American Diabetes Association diagnostic criteria).
- Systolic blood pressure of 130 mmHg and/or diastolic blood pressure 80 mmHg or
higher despite medical treatment with maximal doses of three antihypertensive
medications).
- Refractory hyperlipidemia (acceptable levels of lipids unachievable with diet and
maximum doses of lipid lowering medications).
- Obesity-induced cardiomyopathy.
- Clinically significant obstructive sleep apnea.
- Obesity-related hypoventilation.
- Pseudotumor cerebri (documented idiopathic intracerebral hypertension).
- Severe arthropathy of spine and/or weight-bearing joints (when obesity prohibits
appropriate surgical management of joint dysfunction treatable but for the
obesity).
- Hepatic steatosis without evidence of active inflammation.
- Hypertriglyceridemia
- Polycystic Ovary Syndrome (PCOS)
- Asthma
- Coronary Artery Disease (CAD)
Exclusion Criteria:
- Prior bariatric surgery
- Prior AF catheter ablation
- BMI > 65 kg/m2
- Contraindication to bariatric surgery or AF ablation
- Contraindication to therapeutic anticoagulation
- Sustained AF lasting more than 3 years
- Left atrial diameter of greater than or equal to 60 mm or LA volume greater than or
equal to 60 ml/m2
Ages Eligible for Study
18 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda K Ottoboni, PhD
650-498-5914
Not Recruiting